SAHA Alleviates Diarrhea-Predominant Irritable Bowel Syndrome Through Regulation of the p-STAT3/SERT/5-HT Signaling Pathway
Jian Shen,Bimeng Zhang,Jianjie Chen,Jiazheng Cheng,Jiali Wang,Xianhui Zheng,Yu Lan,Xiaowen Zhang
DOI: https://doi.org/10.2147/JIR.S331303
IF: 4.5
2022-03-10
Journal of Inflammation Research
Abstract:Jian Shen, 1 Bimeng Zhang, 2 Jianjie Chen, 3 Jiazheng Cheng, 1 Jiali Wang, 1 Xianhui Zheng, 1 Yu Lan, 1 Xiaowen Zhang 1 1 Department of Pediatrics, Shuguang Hospital Affiliated to Shanghai Traditional Chinese Medical University, Shanghai, 201203, People's Republic of China; 2 Department of Acupuncture and Moxibustion, Shanghai General Hospital (The First People's Hospital Affiliated to Shanghai Jiaotong University), Shanghai, 200080, People's Republic of China; 3 Department of Internal Medicine, Shuguang Hospital Affiliated to Shanghai Traditional Chinese Medical University, Shanghai, 201203, People's Republic of China Correspondence: Jian Shen Department of Pediatrics, Shuguang Hospital Affiliated to Shanghai Traditional Chinese Medical University, Shanghai, 201203, People's Republic of China Tel +86-21-53821650 Email Objective: Irritable bowel syndrome (IBS) is characterized by abdominal pain, bloating, and stool irregularity. However, its pathophysiological mechanisms, which trigger intestinal motility disorders and diarrhea leading to diarrhea-predominant IBS (D-IBS), remain largely unknown. Methods: In the present study, we established a D-IBS rat model by mother–infant separation combined with restraint stress. Then we exposed the modelled rats to suberoylanilide hydroxamic acid (SAHA) treatment, followed by determination of their visceral sensitivity. Toluidine blue staining served to reveal the effects of SAHA treatment on mast cells of D-IBS model rats. Then we measured the expression of serotonin (5-hydroxytryptamine; 5-HT) and its receptors by ELISA. Results: Construction of short hairpin RNA (sh)-serotonin transporter (SERT) lentivirus vectors verified the regulation of the 5-HT signaling pathway by phosphorylated (p)-STAT/SERT. SAHA treatment of D-IBS model rats reduced the fecal water content, electromyography integral change rate, abdominal withdrawal reflex score, and number of mast cells, as well as the expression of 5-HT type 3A (5-HT3AR), 3B receptor (5-HT3BR), and 4 receptor (5-HT4R) receptors. The treatment also elevated the expression of signal transducer and activator for transcription 3 (STAT3) and SERT. Activation of p-STAT3 may reverse the inhibitory effect of SAHA on the elevated visceral sensitivity of D-IBS model rats. Moreover, SAHA promoted the transcription of SERT through repression of the p-STAT3/5-HT signaling, thereby inhibiting the visceral sensitivity of D-IBS model rats. Conclusion: This study highlights that SAHA treatment can alleviate D-IBS through regulation of the p-STAT3/SERT/5-HT signaling pathway. Keywords: diarrhea type irritable bowel syndrome, SAHA, p-STAT3, SERT, 5-HT Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain, bloating, and stool irregularity. 1,2 As one of the most common gastrointestinal disorders, IBS has a prevalence rate of 10–15% worldwide, bringing a great negative impact on quality of life and work efficiency of affected individuals. 3,4 An abnormal increase in visceral sensitivity is hypothesized to be one of the key pathophysiological mechanisms of IBS, which triggers intestinal motility disorders and diarrhea leading to diarrhea-predominant IBS (D-IBS). 5 To date, there is an incomplete understanding of the mechanistic pathways leading to D-IBS, which has hindered the development of specific and effective therapies. 6 Thus, identifying the underlying mechanism of visceral sensitivity should open new avenues for therapeutics targeting D-IBS. The intestinal neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has demonstrated multiple effects on IBS, including stimulating intestinal secretion and colonic motility. 7 Of note, 5-HT is mainly synthesized in enteric neurons of the gastrointestinal tract, where the serotonin transporter (SERT) mediates its reuptake, as in the central nervous system. Besides, postprandial increases in 5-HT are reported in D-IBS patients 8 5-HT antagonists (such as the 5HT3 antagonist Alosetron) have approval for women with severe D-IBS, despite the risk of causing severe constipation. 9 Accumulating evidence has suggested that histone deacetylase (HDAC) inhibitors play causative roles in multiple clinical disorders. 10 While there are few studies on HDAC inhibitors in IBS, Moloney et al have demonstrated that the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) can normalize the visceral hypersensitivity caused by early life stress. 11 This finding provides evidence justifying further efforts to develop HDAC inhibitor for treating IBS. Besides, there is prior evidence for the invo -Abstract Truncated-
immunology